Work

First-line treatment with bevacizumab (B) and high dose (HD) bolus aldesleukin (IL-2) in metastatic renal cell carcinoma (mRCC) patients (Pts)

Year: 2007

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2007.25.18_suppl.15524

Authors: M. S. Ernstoff, M. M. Regan, D. F. McDermott, J. A. Sosman, J. P. Dutcher, J. I. Clark, T. S. Crocenzi, A. Ochoa, M. B. Atkins

Institutions: Dartmouth–Hitchcock Medical Center, Beth Israel Deaconess Medical Center, Loyola University Chicago, Dana-Farber Cancer Institute, Vanderbilt-Ingram Cancer Center, Louisiana State University Health Sciences Center New Orleans

Language: English

Topic: Renal cell carcinoma treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2229434335

Cites:

Cited by: 4

Related to: 10